This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

O. W. JONES III

Arch Ophthalmol. 1961;66(1):29-36.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A recent study of a potent new antihypertensive agent pheniprazine hydrochloride (Catron *) indicated that some of the patients treated with this drug developed color blindness and decreased visual acuity which improved spontaneously when the drug was discontinued.¹ This report deals in more detail with the ophthalmological findings in these and other patients and, in addition, pathological findings are presented which document the toxic nature of the visual defects described.

Materials and Methods

Patients receiving pheniprazine hydrochloride who developed disturbances of visual function were seen in consultation by members of the staff of the Ophthalmology Branch at the National Institutes of Health. Each patient received a complete ophthalmological examination which included the evaluation of color vision with the Hardy-Rand-Rittler Pseudoisochromatic Plates and in some cases the Farnsworth D-15 Panel was used.

Autopsy material available from one patient (Case 8) was fixed in 10% formalin 16 hours after death and studied . . . [Full Text PDF of this Article]

Author Affiliations
Bethesda, Md.

From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, U.S. Public Health Service, U.S. Department of Health, Education and Welfare.

Footnotes
Submitted for publication Feb. 27, 1961.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?